Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Core Insights - Tarsus Pharmaceuticals is advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, a significant eye disease with no FDA-approved therapy, with plans to initiate a Phase 2 study in the second half of 2025 [1][6][11] Company Updates - Tarsus reported that 2024 was a groundbreaking year with XDEMVY achieving consistent quarter-over-quarter revenue growth, rapid physician adoption, and broad payer coverage, generating over $113 million in net product sales during the first nine months of 2024 [3][6] - The company delivered more than 104,000 bottles of XDEMVY to patients, with over 13,000 Eye Care Professionals prescribing it, and more than 70% of these professionals writing prescriptions for multiple patients [6] - Tarsus plans to enhance its strategic initiatives in 2025, focusing on generating new evidence for XDEMVY and pursuing Ocular Rosacea as a transformative opportunity in eye care [3][6] Product Information - XDEMVY (lotilaner ophthalmic solution, 0.25%) is designed to treat Demodex blepharitis by targeting Demodex mite infestation, with pivotal trials showing significant improvements in key endpoints [9][10] - TP-04 is an investigational formulation of lotilaner aimed at treating Ocular Rosacea, which affects approximately 15-18 million Americans, with a clear regulatory path established based on FDA feedback [6][11] Future Plans - The company is on track for potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027 and anticipates sharing results from a prevalence study in Japan in 2025 [14] - Tarsus is also developing TP-05, an oral systemic formulation of lotilaner, aimed at preventing Lyme disease transmission [12][13]